Avenue Therapeutics Inc (ATXI)
1.93
+0.05
(+2.66%)
USD |
NASDAQ |
Nov 15, 16:00
1.95
+0.02
(+1.04%)
After-Hours: 20:00
Avenue Therapeutics Research and Development Expense (Quarterly): 1.361M for June 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 1.361M |
| March 31, 2024 | 2.392M |
| December 31, 2023 | 0.982M |
| September 30, 2023 | 0.907M |
| June 30, 2023 | 3.027M |
| March 31, 2023 | 5.445M |
| December 31, 2022 | 0.545M |
| September 30, 2022 | 0.194M |
| June 30, 2022 | 0.151M |
| March 31, 2022 | 1.808M |
| December 31, 2021 | 0.39M |
| September 30, 2021 | 0.278M |
| June 30, 2021 | 0.328M |
| March 31, 2021 | 0.258M |
| December 31, 2020 | 0.484M |
| September 30, 2020 | 0.466M |
| June 30, 2020 | 1.219M |
| Date | Value |
|---|---|
| March 31, 2020 | 0.697M |
| December 31, 2019 | 4.855M |
| September 30, 2019 | 1.706M |
| June 30, 2019 | 6.392M |
| March 31, 2019 | 10.24M |
| December 31, 2018 | 2.715M |
| September 30, 2018 | 1.788M |
| June 30, 2018 | 3.754M |
| March 31, 2018 | 9.439M |
| December 31, 2017 | 5.221M |
| September 30, 2017 | 2.00M |
| June 30, 2017 | 0.447M |
| March 31, 2017 | 0.133M |
| December 31, 2016 | 0.212M |
| September 30, 2016 | 0.183M |
| June 30, 2016 | 0.421M |
| March 31, 2016 | 0.564M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.151M
Minimum
Jun 2022
5.445M
Maximum
Mar 2023
1.357M
Average
0.697M
Median
Mar 2020
Research and Development Expense (Quarterly) Benchmarks
| Fortress Biotech Inc | 12.67M |
| NovaBay Pharmaceuticals Inc | 0.004M |
| Palatin Technologies Inc | 4.672M |
| iBio Inc | 1.14M |
| Theriva Biologics Inc | 2.953M |